BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35876920)

  • 1. Intervention for Hepatic and Pulmonary Metastases in Breast Cancer Patients: Prospective, Multi-institutional Registry Study-IMET, Protocol MF 14-02.
    Soran A; Ozbas S; Ozcinar B; Isik A; Dogan L; Senol K; Dag A; Karanlik H; Aytac O; Karadeniz Cakmak G; Dalci K; Dogan M; Sezer YA; Gokgoz S; Ozyar E; Sezgin E;
    Ann Surg Oncol; 2022 Oct; 29(10):6327-6336. PubMed ID: 35876920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
    Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Brain Metastasis-Free Interval in Patients with Breast Cancer Brain Metastases.
    Hulsbergen AFC; Lamba N; Claes A; Kavouridis VK; Lin NU; Smith TR; Verhoeff JJC; Broekman MLD
    World Neurosurg; 2019 Aug; 128():e157-e164. PubMed ID: 31035019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    Yamamura J; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hashimoto Y; Komoike Y
    BMC Cancer; 2021 Apr; 21(1):476. PubMed ID: 33926418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01.
    Soran A; Ozmen V; Ozbas S; Karanlik H; Muslumanoglu M; Igci A; Canturk Z; Utkan Z; Ozaslan C; Evrensel T; Uras C; Aksaz E; Soyder A; Ugurlu U; Col C; Cabioglu N; Bozkurt B; Uzunkoy A; Koksal N; Gulluoglu BM; Unal B; Atalay C; Yıldırım E; Erdem E; Salimoglu S; Sezer A; Koyuncu A; Gurleyik G; Alagol H; Ulufi N; Berberoglu U; Dulger M; Cengiz O; Sezgin E; Johnson R
    Ann Surg Oncol; 2018 Oct; 25(11):3141-3149. PubMed ID: 29777404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
    JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
    Press DJ; Miller ME; Liederbach E; Yao K; Huo D
    Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.
    Sihto H; Lundin J; Lundin M; Lehtimäki T; Ristimäki A; Holli K; Sailas L; Kataja V; Turpeenniemi-Hujanen T; Isola J; Heikkilä P; Joensuu H
    Breast Cancer Res; 2011 Sep; 13(5):R87. PubMed ID: 21914172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.
    Ge QD; Lv N; Kong YN; Xie XH; He N; Xie XM; Wei WD
    Asian Pac J Cancer Prev; 2012; 13(10):5081-6. PubMed ID: 23244114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer.
    van Uden DJP; van Maaren MC; Strobbe LJA; Bult P; van der Hoeven JJ; Siesling S; de Wilt JHW; Blanken-Peeters CFJM
    Breast Cancer Res; 2019 Oct; 21(1):113. PubMed ID: 31623649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.
    St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F
    Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry.
    Laakmann E; Witzel I; Neunhöffer T; Park-Simon TW; Weide R; Riecke K; Polasik A; Schmidt M; Puppe J; Mundhenke C; Lübbe K; Hesse T; Thill M; Zahm DM; Denkert C; Fehm T; Nekljudova V; Rey J; Loibl S; Müller V
    ESMO Open; 2022 Jun; 7(3):100495. PubMed ID: 35653983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes.
    Chun YS; Mizuno T; Cloyd JM; Ha MJ; Omichi K; Tzeng CD; Aloia TA; Ueno NT; Kuerer HM; Barcenas CH; Vauthey JN
    Eur J Surg Oncol; 2020 Sep; 46(9):1588-1595. PubMed ID: 32253074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.
    Olson EM; Najita JS; Sohl J; Arnaout A; Burstein HJ; Winer EP; Lin NU
    Breast; 2013 Aug; 22(4):525-31. PubMed ID: 23352568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
    Yardley DA; Kaufman PA; Brufsky A; Yood MU; Rugo H; Mayer M; Quah C; Yoo B; Tripathy D
    Breast Cancer Res Treat; 2014 Jun; 145(3):725-34. PubMed ID: 24706168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant.
    He M; Li JJ; Zuo WJ; Ji L; Jiang YZ; Hu XC; Wang ZH; Shao ZM
    Cancer Med; 2019 Oct; 8(14):6212-6220. PubMed ID: 31373147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.